Co-Founder/CEO
Menten AI
Menten AI develops peptide therapeutics using a generative AI platform that combines machine learning with physics-based molecular modeling to create novel drug-like compounds. This approach addresses the limitations of traditional drug design by enabling rapid and efficient discovery of potent peptides for previously undruggable targets, achieving significant improvements in sampling power and hit success rates.
- Artificial Intelligence
- Biotechnology
Updated yesterday
Funding
Raised to date
$4.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Menten AI develops peptide therapeutics using a generative AI platform that combines machine learning with physics-based molecular modeling to create novel drug-like compounds. This approach addresses the limitations of traditional drug design by enabling rapid and efficient discovery of potent peptides for previously undruggable targets, achieving significant improvements in sampling power and hit success rates.